$KMTS

KESTRA MEDICAL TECHNOLOGIES, LTD.

Kestra Medical Technologies is a wearable medical device and digital healthcare company based in Kirkland, Washington. Its Cardiac Recovery System platform supports patients at elevated risk of sudden cardiac arrest during recovery. The platform centers on the ASSURE Wearable Cardioverter Defibrillator, which monitors heart rhythms and automatically delivers a shock when it detects life-threatening ventricular arrhythmias. The platform also includes the ASSURE patient application, Kestra CareStation remote patient management platform, Heart Alert Services and ASSURE Assist. These tools support communication between patients and healthcare providers, provide patient data and alerts, and facilitate emergency response. Kestra derives nearly all its revenue by billing Medicare, Medicaid, private payors and other healthcare organizations for leasing the ASSURE device to patients. It also bills patients for costs not covered by third-party payors.

AlphAI earnings readQ1 FY2027 · SEP 14Kestra Medical Technologies Reports First Quarter Fiscal 2027 Financial ResultsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

2
0
0
—
$6.6M
Mahboob Vaseem
89%
See all $KMTS insider activity →
Med

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

Mahboob Vaseem sold $2.4M of KMTS

Mahboob Vaseem (Chief Financial Officer) sold 79,500 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $30.30 ($30.04–$30.60, $2.41M total) across 3 trades over 2026-10-27 to 2026-10-29 under a Rule 10b5-1 trading plan.

Umberger Traci S sold $901K of KMTS

Umberger Traci S (See Remarks) sold 30,000 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at $30.03 ($0.90M total) on 2026-10-27 under a Rule 10b5-1 trading plan.

KMTS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning KMTS (KESTRA MEDICAL TECHNOLOGIES, LTD.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.

Recent KMTS coverage spans earnings, insider activity and technology.

In the last 30 days, KMTS insiders filed 9 SEC Form 4 transactions — no purchases and 9 sales ($6.6M). The most active reporter was Mahboob Vaseem, Chief Financial Officer, with 3 filings. 89% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving KMTS

  • Positive clinical outcomes suggest strong product efficacy and could drive demand for the wearable defibrillator.

    investing.com · Nov 16, 2026

  • The insider sale may create modest downward pressure on KMTS as investors price in potential insider sentiment.

    SEC EDGAR · Oct 29, 2026

  • The filing is a routine 10b5-1 open-market sale by an officer/director, which typically has limited directional signal but can add near-term supply overhang.

    SEC EDGAR · Oct 29, 2026

  • The insider sale may create modest selling pressure on KMTS.

    SEC EDGAR · Oct 22, 2026

  • Positive analyst coverage is likely to lift the stock as investors price in the higher target.

    investing.com · Oct 20, 2026

AlphAI scores every news story that mentions KMTS with an AI model for sentiment and relevance, and aggregates insider trades from KESTRA MEDICAL TECHNOLOGIES, LTD.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $KMTS

Score
$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSMedAI 8/10

Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60%

Kestra Medical Technologies (KMTS) reported Q1 2027 revenue growth of 60% but saw increased operating expenses and net loss. The company raised its full-year guidance to $141M, expecting 48% growth. Gross margins expanded for 11 consecutive quarters, with confidence in reaching mid-70% margins. R&D spend increased significantly due to a late-stage project but is expected to normalize. Management attributed growth to prescription volume, in-network mix, and field team expansion.

Related tickers